Divergent systemic and airway mucosal adaptive immunity to SARS-CoV-2 in African adults
This study demonstrates that in African adults, systemic antibody responses strongly correlate with lung immunity and protection against severe COVID-19, whereas nasal immunity is driven by distinct local IgA responses and tissue-resident T cells that are not predicted by systemic or lower respiratory tract immunity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human body defends itself against invading germs with a layered immune system. Some defenses patrol the bloodstream, acting like a national guard ready to rush to any organ under attack. Others are stationed directly at the front lines, such as the lining of the nose and lungs, forming a local militia that fights infection right where it enters. For years, scientists have relied on measuring the national guard—the antibodies circulating in blood—to judge how well a person is protected against viruses like SARS-CoV-2. This approach works well for predicting who will avoid severe lung disease, but it has become less reliable for predicting who will catch the virus in the first place or spread it to others. The puzzle is why a strong defense in the blood does not always mean a strong defense in the nose, and whether this difference holds true for people living with HIV, a condition that can weaken the immune system.
A team of researchers in Malawi set out to solve this puzzle by looking at the immune system in three different places at once: the blood, the fluid lining the nose, and the fluid deep inside the lungs. They studied 91 adults, half of whom were living with HIV but were healthy and taking medication to keep the virus under control, and half of whom did not have HIV. By collecting samples from all three areas simultaneously, the scientists could see exactly how the immune responses in the nose and lungs compared to the responses in the blood. They measured the specific antibodies and immune cells that target the virus to see if they were the same everywhere or if they acted differently depending on where they were found.
The study revealed a clear split in how the body protects itself. The antibodies found in the blood, which are mostly a type called IgG, matched very closely with the antibodies found deep in the lungs. When the blood had high levels of these antibodies, the lungs did too. This explains why blood tests are good at predicting protection against severe pneumonia; the blood and the lungs seem to be part of the same defensive network. However, the antibodies in the nose told a different story. The levels of antibodies in the nose did not match the levels in the blood or the lungs. Instead, the nose relied heavily on a different type of antibody, called IgA, to stop the virus from attaching to cells. The amount of this IgA in the nose could not be predicted by looking at the blood. Even though the blood showed strong immunity, the nose often had very little of the specific protection needed to block the virus from taking hold.
This separation was true for everyone in the study, regardless of whether they had HIV. The researchers found that people with HIV who were taking effective treatment had immune responses in their blood, nose, and lungs that were just as strong as those without HIV. Their bodies were able to mount the same local defenses in the nose and the same systemic defenses in the blood as anyone else. The study also looked at T cells, another part of the immune system that hunts down infected cells. These cells were found in much higher numbers deep in the lungs than in the blood. Furthermore, the T cells in the lungs looked different from those in the blood; they appeared to be settled in the tissue, ready to act immediately, rather than circulating around the body. This means that a blood test cannot tell you how many of these specialized lung defenders are actually waiting in the airways.
The findings suggest that the immune system is not a single, uniform shield but a collection of distinct defenses that operate independently in different parts of the body. While a strong blood response is a good sign that the lungs will be protected from severe illness, it does not guarantee that the nose will be able to stop the virus from entering. This helps explain why people with high levels of antibodies in their blood can still get infected in their nose and pass the virus to others. The research indicates that to truly stop the spread of the virus, future vaccines or treatments may need to focus on boosting the local defenses in the nose, rather than just relying on the antibodies circulating in the blood. For people with well-controlled HIV, the study offers reassurance that their immune systems are capable of generating these necessary local defenses just as effectively as those without the virus.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.